Return to Vaccination News Home Page __» Right-click to "open in new window"
Subscribe to the Vaccination NewsLetter
View past & current Scandals (columns by Sandy Mintz)
Search This Site using keywords
http://portland.bizjournals.com/portland/stories/2003/06/16/daily25.html
Bioject, which last year moved its headquarters to New Jersey, maintains the majority of its operations in Portland.
Bioject (Nasdaq: BJCT) will supply the government's Vaccine Research Center, National Institute of Allergy and Infectious Diseases/National Institutes of Health, with the non-exclusive right to use the B-2000 in clinical trials for experimental vaccines against HIV and Ebola for up to a 36-month period. In addition, Bioject will provide training, clinical and administrative support for these clinical trials. Bioject will be reimbursed between $250,000 and $1 million per year for its services.
"DNA-based vaccines represent an important target market for our technology and this agreement provides us with an important platform to build upon, providing us with short-term revenues and the opportunity for future licensing agreements upon the successful development of the HIV and Ebola vaccines," said Jim O'Shea, Bioject's chairman, president, and CEO.
Return to Vaccination News Home Page __» Right-click to "open in new window"
DISCLAIMER: All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice. The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.